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Abstract
Objective: The subject of this study is to determine the frequency of sonr-
serologic markers of autoimmune diseases and clinical manifestations in
vitiligo patients that u,e:e referring to Afzalipour Hospital in Kerman.
nTaterials and methods:This is a cross-sectional and descriptive study that is
carried out during 6 month fiorr December, 1395 to May, 1396. for sir.
months. In this studv. tl-re dernographic characteristic of patients (age.
gender, history of autoirnmune diseases in themselves and Family), clinicai
characteristics of the disease (vasi score, duration of disease, location of thc
lesion), some serologic markers of autoimmune diseases (FBS, TSH. Ant-
TPO, ANA) u,ere collected and the data were analyzed through chi squar;
test and SPSS softu,are version 16.
Results:there \\'ere 100 vitiligo patients in this study,and 59Yo of this patier-rt--
were female. The mean age in enrolled was 29.34, the minimun age of thes:
patients was 1 lear old and their maximum age was 70 years old.. Th;
average duration of the disease in patients was 7.2850 years with a minin-iur:.
of 6 months and a maximurn of 40 years. The median VASI SCORE was 3y
with a minimum of 10 and a maximum of 100, 27oA of patients had VAS,
SCORE less than 10.14o,'o of patients had VASI SCORE, between 109'o an;
50o/o and29o/o of patients had VASI SCORE Over 50.22% of patients ha;
lristory of autoimmune disease in then-rselves or in their family. 22o/o of thes-
patients had positive ANA. 60/o of these patients had high FBS. 1990 
-,
patients had high TSH. 18% ofpatients had high Anti TPO. The n.rost les,,:
location rvas in patient's head and neck(43o/o). 4l% of patient had lesior. .
their tlunk,33o had lesions in their proxirnal of upper limbs, 1690 1",-.
lesions in their distal of upper limbs, 22oh had lesions in their proxirn:'..
lower limbs, 34o/ohad lesions in the distal of lower limb and 3lYohad lesions
in their joints. lesion location had no association rvith ANA, TSH. Anti TPO
, FBS.
Conclusion: ANA, TSH, FBS, Anti TPO had no association u ith VASI
Score.also There was no relationship between patients'age and ANA.
TSH,Anti TPO and FBS .u,hile ANA, FBS, TSH, anti TPO and gender \\'ere
irrevelence,. There was a significant relationship between ANA and duration
of the disease which is true for TSH (P value: 0.039), and also true for FBS
(P value: 0.000)as vu'ell.There was a significant relationship betlveen anti
TPO and duration of disease (P value: 0.016). There \vas no signiflcart
relationship betu,een FBS, Anti TPO, ANA and autoiillnulle disease in tire
patient or hisiher family, but there was a significant relevence between TSH
and history The autoimmune disease in patient l-rimself or his famiiy tP
Value: 0.00O).finally the location of lesion has no association with Ai.i"A.
TSH, Anti TPO. FBS.
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